Posted by ABMN Staff on Apr 18th, 2024
Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Separately, Cantor...
More of this article »